Development of sensitive immunoassays to detect amylin and amylin-like peptides in unextracted plasma

Clinical Chemistry

Volumn 42, Issue 4, 1996, Pages 576-585

  Percy, Amy J ^a   Trainor, Deirdre A ^a   Rittenhouse, Judith ^a   Phelps, Julie ^a   Koda, Joy E ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

amylin like peptides; diabetes; enzyme immunoassay; immunofluorometric assay; islet amyloid polypeptide; monoclonal antibodies; oral glucose tolerance test

Indexed keywords

AMYLIN; INSULIN;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; IMMUNOASSAY; IMPAIRED GLUCOSE TOLERANCE; NORMAL HUMAN; PANCREAS SECRETION; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION;

EID: 0029985970     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/42.4.576     Document Type: Article

References (38)

1. Cooper GJS, Willis AC, Clark A, Turner RC, Sim KB. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A 1987;84:8628-32.
2. Cooper GJS, Leighton B, Dimitriadis GD, Parry-Billings M, Kowalchuk JM, Howland K, et al. Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc Natl Acad Sci U S A 1988;85:7763-6.
3. Roberts A, Leighton B, Todd JA, Cockburn D, Schofield PN, Sutton R, et al. Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus. Proc Natl Acad Sci U S A 1989;86:9662-6.
4. Kahn SE, Fujimoto WY, D'Alessio DA, Ensinck JW, Porte D. Glucose stimulates and potentiates islet amyloid polypeptide secretion by the β-cell. Horm Metab Res 1991;23:577-80.
5. Castillo MJ, Scheen AJ, Lefèbvre PJ. Amylin/islet amyloid polypeptide: biochemistry, physiology, patho-physiology. Diabete Metab 1995;21:3-25.
6. Akimoto K, Nakazato M, Matsukura S, Hayakawa K. Plasma concentration of islet amyloid polypeptide in healthy children and patients with insulin-dependent diabetes mellitus. Acta Paediatr 1993;82:310-1.
7. Koda JE, Fineman M, Rink TJ, Dailey GE, Muchmore DB, Linarelli LG. Amylin concentrations and glucose control. Lancet 1992;339: 1179-80.
8. Sanke T, Hanabusa T, Nakano Y, Oki C, Okai K, Nishimura S, et al. Plasma islet amyloid polypeptide (amylin) levels and their responses to oral glucose in type-2 (non-insulin-dependent) diabetic patients. Diabetologia 1991;34:129-32.
9. Ludvik B, Lell B, Hartter E, Schnack C, Prager R. Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes. Diabetes 1991;40:615-9.
10. Huang HJS, Young AA, Koda JE, Tulp OL, Johnson MJ, Cooper GJS. Hyperamylinemia, hyperinsulinemia, and insulin resistance in genetically obese LA/N-cp rats. Hypertension 1992;19:1101-9.
11. Enoki S, Mitsukawa T, Takemura J, Nakazato M, Aburaya J, Toshimori H, Matsukara S. Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 1992;15: 97-102.
12. Kautzky-Willer A, Thomaseth K, Pacini G, Clodi M, Ludvik B, Streli C, et al. Role of islet amyloid polypeptide secretion in insulin-resistant humans. Diabetologia 1994;37:188-94.
13. Butler PC, Chou J, Carter B, Wang Y, Bu B, Chang D, et al. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 1990;39:752-6.
14. Blackard WG, Clore JN, Kellum JM. Amylin/insulin secretory rations in morbidly obese man: inverse relationship with glucose disappearance rate. J Clin Endocrinol Metab 1994;78:1257-60.
15. Young AA. Amylin regulation of fuel metabolism. J Cell Biochem 1994;55(Suppl):12-8.
16. Young AA, Gedulin B, Vine W, Percy A, Rink TJ. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 1995;38:642-8.
17. Brown K, Menius A, Sandefer E, Edwards J, James M. The effects of amylin on changes in plasma glucose and gastric emptying following an oral glucose load in conscious dogs [Abstract]. Diabetes 1994;43(Suppl 1):172A.
18. Kolterman OG, Gottlieb A, Moyses C, Colburn W. Reduction of post-prandial hyperglycemia in subjects with type I diabetes mellitus by intravenous infusion of AC137, a human amylin analogue. Diabetes Care 1995;18:1179-82.
19. Nakazato M, Asai J, Kangawa K, Matsukura S, Matsuo H. Establishment of radioimmunoassay for human islet amyloid polypeptide and its tissue content and plasma concentration. Biochem Biophys Res Commun 1989;164:394-9.
20. Shiomi K, Nakazato M, Miyazato M, Kangawa K, Matsuo H, Matsukura S. Establishment of hypersensitive radioimmunoassay for islet amyloid polypeptide using antiserum specific for its N-terminal region. Biochem Biophys Res Commun 1992;186: 1065-73.
21. Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kuenburg E, et al. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia 1991;34:52-4.
22. van Hulst KL, Hackeng WHL, Höppener JWM, van Jaarsveld BC, Nieuwenhuis MG, Blankenstein MA, Lips CJM. An improved method for the determination of islet amyloid polypeptide levels in plasma. Ann Clin Biochem 1994;31:165-70.
23. Boscato LM, Stuart MC. Heterophilic antibodies: a problem for all immunoassays. Clin Chem 1988;34:27-33.
24. Boscato LM, Stuart MC. Incidence and specificity of interference in two-site immunoassays. Clin Chem 1986;32:1491-5.
25. Kearney JF, Radbrach A, Liesegany B, Rajewsky K. A new mouse myeloma that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J Immunol 1979;123:1548-50.
26. Gerhard W. Fusion of cells in suspension and outgrowth of hybrids in conditioned medium. In: Kennet R, McKearn TJ, Bechtol KG, eds. Monoclonal antibodies. New York: Plenum Press, 1980:370.
27. Hunter WM, Greenwood FC. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature 1962; 194:495-6.
28. Hunter WM. The preparation of radioiodinated proteins of high activity, their reactions with antibody in vitro: the radioimmunoassay. In: Weir DM, ed. Handbook of experimental immunology. Oxford, UK: Blackwell Scientific, 1967:608-54.
29. WHO Expert Committee on Diabetes Mellitus, second report. WHO Tech Rep Ser 1980;646:1-80.
30. Diabetes mellitus. Report of WHO Study Group. WHO Tech Rep Ser 1985;727:1-113.
31. Percy AJ, Trainor D, Rittenhouse J, Janes S, Koda JE. Sensitive two-site enzyme immunoassays for amylin and amylin-like peptides in human plasma [Abstract]. Diabetologia 1994;37(Suppl 1):A117.
32. Miyazato M, Nakazato M, Shiomi K, Aburaya J, Toshimori H, Kangawa K, et al. Identification and characterization of islet amyloid polypeptide in mammalian gastrointestinal tract. Biochem Biophys Res Commun 1991;181:293-300.
33. Huang HJS, Young AA, Johnson JM, Gedulin B, Cooper GJS. Amylin mRNA in the autoimmune diabetic BB/Wor and insulin-resistant LA/N-cp rat [Abstract]. Diabetes 1991;40(Suppl 1):46A.
34. Ludvik B, Clodi M, Kautzky-Willer A, Schuller M, Graf H, Hartter E, et al. Increased levels of circulating islet amyloid polypeptide in patients with chronic renal failure have no effect on insulin secretion. J Clin Invest 1994;94:2045-50.
35. Permert J, Larsson J, Westermark GT, Herrington MK, Christmanson L, Pour PM, et al. Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Engl J Med 1994;330:313-8.
36. Nakazato M, Miyazato M, Asai J, Mitsudawa T, Kangawa K, Matsuo H, Matsukura S. Islet amyloid polypeptide, a novel pancreatic peptide, is a circulating hormone secreted under glucose stimulation. Biochem Biophys Res Commun 1990;169: 713-8.
37. Mitsukawa T, Takemura J, Asai J, Nakazato M, Kangawa K, Matsuo H, Matsukura S. Islet amyloid polypeptide response to glucose, insulin, and somatostatin analogue administration. Diabetes 1990;39:639-42.
38. Eriksson J, Nakazato M, Miyazato M, Shiomi K, Matsukura S, Groop L. Islet amyloid polypeptide plasma concentrations in individuals at increased risk of developing type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992;35:291-3.